Your session is about to expire
← Back to Search
IFN-alpha2a for Myeloproliferative Disorder
Study Summary
This trial is testing if Pegasys can help control the disease in patients with essential thrombocythemia, polycythemia vera, myelofibrosis/myeloid metaplasia, and Philadelphia chromosome-negative chronic myelogenous leukemia. The trial will also study the safety of this treatment.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are participating in the experiment?
"At this juncture, enrollment in the clinical trial is currently not available. The study began on April 7th 2005 and was revised as recently as August 24th 2022. Likewise, there are 113 trials recruiting participants with myeloproliferative disorders and 34 medical studies using IFN-alpha2a actively enrolling patients."
What potential side effects have been observed with IFN-alpha2a treatments?
"Although there is not any clinical evidence that IFN-alpha2a is effective, the data in regards to safety suggests a score of 2."
In what conditions is IFN-alpha2a typically prescribed?
"IFN-alpha2a is a therapeutic agent employed to combat hematological malignancies as well chronic hepatitis b and C, non-Hodgkin's lymphoma, follicular lymphoma."
Are there still opportunities for people to volunteer for this experiment?
"This research is not currently enrolling patients. It was first posted on April 7th 2005 and underwent its most recent alterations in August 24th 2022. For those looking for other clinical trials, 113 studies related to myeloproliferative disorders are actively enlisting candidates and 34 trials involving IFN-alpha2a are also recruiting volunteers."
Are there any other investigations which have been conducted with IFN-alpha2a?
"Currently, 34 clinical trials are being conducted for IFN-alpha2a with 11 of them in the advanced phase 3. Buffalo, New york is the epicentre of these studies but there are also many other study centres located across 3486 different sites."
Share this study with friends
Copy Link
Messenger